TWST$30.12
Chart
Performance
Key Stats
AI TWST Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldTwist Bioscience shows potential in the synthetic biology space, but current financial performance indicates significant losses and a negative outlook. While there are growth opportunities, the lack of profitability and high cash burn warrant caution.
Thematic
Twist Bioscience operates in the rapidly growing synthetic biology market, crucial for advancements in diagnostics, therapeutics, and bio-based materials. The company's DNA synthesis platform has broad applications.
Fundamental
Twist Bioscience exhibits significant revenue growth but consistently reports substantial net losses and negative free cash flow, indicating high operating expenses and a lack of profitability. The company's cash position is decreasing, but still provides a runway.
Technical
The stock is trading below key moving averages and exhibits bearish momentum indicators, suggesting potential for further downside in the short term. Support levels are being tested.
| Factor | Score |
|---|---|
| Synthetic Biology Market Growth | 90 |
| DNA Synthesis Technology | 85 |
| Applications in Healthcare | 80 |
| Emerging Technologies | 65 |
| Competitive Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 75 |
| Balance Sheet Health | 80 |
| Cash Flow | 20 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 35 |
| Support & Resistance | 45 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Potential Undervaluation
The Price-to-Sales (PS) ratio of 7.9 is lower than the historical average of 10.4 (based on 2021 data), suggesting a potential undervaluation compared to its past.
Strong Cash Position
The company has a significant cash and cash equivalents position of $226.3 million, providing ample liquidity and financial flexibility for future operations and investments.
Bearish Points (8)
Consistent Net Losses
The company has consistently reported net losses, with a net income of -$208.7 million in 2024 and a TTM net income of -$105.6 million, indicating ongoing profitability challenges.
High Price-to-Sales Ratio
The current Price-to-Sales (PS) ratio of 7.9 is significantly higher than its 2021 PS ratio of 48.4, but still indicates a premium valuation relative to its revenue, especially considering the net losses.
Calendar
August 2025
4
Next Earnings Date
H: $-0.52
A: $-0.57
L: $-0.61
H: 98.00M
A: 95.64M
L: 94.00M
Profile
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Seasonals
Price Target
48.42 USD
The 39 analysts offering 1 year price forecasts for TWST have a max estimate of 62.00 and a min estimate of 33.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Parent company of Integrated DNA Technologies (IDT), a primary direct competitor to Twist Bioscience in the DNA synthesis and custom oligo market.
Weight: 90
Dominant player in DNA sequencing, a key application area for Twist Bioscience's synthetic DNA products (e.g., target enrichment, controls). Both serve the genomics research market.
Weight: 88
A leading global provider of scientific instrumentation, reagents, and services; competes with TWST in some life science tools segments and serves the same broad customer base.
Weight: 85
A major synthetic biology company focusing on cell programming for various industries; both operate in the broader synthetic biology ecosystem, with potential for partnership or competition.